Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biontech Se ADR
(NQ:
BNTX
)
85.94
+1.26 (+1.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
265,281
Open
85.05
Bid (Size)
82.59 (2)
Ask (Size)
86.00 (1)
Prev. Close
84.68
Today's Range
84.92 - 86.14
52wk Range
78.02 - 125.83
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
BioNTech to Report Second Quarter 2024 Financial Results and Corporate Update on August 5, 2024
July 22, 2024
From
BioNTech SE
Via
GlobeNewswire
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
Performance
YTD
-23.50%
-23.50%
1 Month
+4.14%
+4.14%
3 Month
-1.46%
-1.46%
6 Month
-9.35%
-9.35%
1 Year
-18.15%
-18.15%
More News
Read More
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
July 03, 2024
Via
Benzinga
Exposures
COVID-19
Evaluating BioNTech: Insights From 12 Financial Analysts
June 26, 2024
Via
Benzinga
Evaluating BioNTech: Insights From 15 Financial Analysts
June 10, 2024
Via
Benzinga
London High Court Ruling Fuels Pfizer And Moderna Legal Dispute Over COVID-19 Vaccine Patents
July 02, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
July 02, 2024
Via
MarketBeat
Topics
ETFs
Exposures
COVID-19
3 Nasdaq Stocks to Sell in July Before They Crash & Burn
July 02, 2024
Via
InvestorPlace
Surprise! 3 Stocks That Are Outperforming Nvidia in 2024.
July 01, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
3 Dividend Stocks Yielding Over 3% With Multi-Decade Payout Growth Streaks
July 01, 2024
Via
InvestorPlace
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
June 27, 2024
Via
Benzinga
Exposures
Product Safety
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
Pfizer Inc.
Via
Business Wire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
June 27, 2024
From
BioNTech SE
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
June 24, 2024
Via
Benzinga
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
June 24, 2024
From
BioNTech SE
Via
GlobeNewswire
GameStop And First Solar Were Among The 10 Biggest Large Cap Losers Last Week (June 16-June 22): Are These In Your Portfolio?
June 23, 2024
Via
Benzinga
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
June 18, 2024
Via
Benzinga
Exposures
COVID-19
Why Is Pfizer Partner BioNTech Stock Trading Lower On Monday?
June 17, 2024
Via
Benzinga
Exposures
Product Safety
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
June 07, 2024
Via
Benzinga
Exposures
COVID-19
Product Safety
Meme Stocks Surge Led by ‘Roaring Kitty’ and Social Media Buzz on Reddit (NYSE: RDDT), GME, DYAI, AMC, PRSO, NVAX
June 06, 2024
Via
AB Newswire
Dyadic International Inc. (NASDAQ: DYAI) Hits New 52-Week High Amidst Golden Cross, Bullish Swing Patterns and Bird Flu Concerns
June 06, 2024
Via
AB Newswire
What's Going On With Novavax Stock?
June 05, 2024
Via
Benzinga
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
June 01, 2024
Via
Talk Markets
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
Genmab A/S
Via
Business Wire
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
June 01, 2024
From
BioNTech SE
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.